Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CFB | P00751 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13096520 | 0.80 | CHRNB2 (0.54) | CYP19A1CFBCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3666059 | 0.76 | RIPK1 (0.44) | CYP19A1CFB | |
| SCHEMBL3663312 | 0.76 | CFB (0.46) | CYP19A1CFBHRH3CHKASLC6A2 | |
| SCHEMBL19539601 | 0.75 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL21048052 | 0.71 | RIPK1 (0.49) | CYP19A1 | |
| SCHEMBL1653726 | 0.70 | GPR119 (0.47) | — | |
| SCHEMBL8993390 | 0.70 | ESR2 (0.47) | CYP19A1 | |
| SCHEMBL16891471 | 0.70 | RIPK1 (0.48) | CYP19A1CFB | |
| SCHEMBL6242317 | 0.69 | CFB (0.48) | CYP19A1CFBHRH3 | |
| SCHEMBL16880537 | 0.69 | CFB (0.43) | CYP19A1CFBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240028-B1 | Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical | INTRA CELLULAR THERAPIES INC (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20150197524-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-07-16 | — | — | US | disclosed |
| US-8846693-B2 | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197524-A1 | ORGANIC COMPOUNDS | OPRD1, HTR1D, DRD1 | CYP19A1 18/4885CFB 4660/4885HRH3 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.